ACT16903

Research code: ACT16903
Research name: Phase 2 non-randomised, open-label, multicentre study evaluating the clinical benefit of SAR444245 (THOR-707) in combination with other anticancer drugs in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Indication: head and neck cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with head and neck cancer - failure of previous therapies
Research drug: PD-1 immunotherapy + research drug from the immunomodulatory group